Oncosil Medical (OSL.AX) Hisse Fiyat
Oncosil Medical Fiyat
Oncosil Medical şirketinin geliri, son 19 yılda yıllık %0,2 daralarak 1,68 M AUD seviyesine geriledi. Oncosil Medical için net marj, %-644,5 ile birkaç yıl önceki %-4.627,9 seviyesine göre yükseldi.
Oncosil Medical hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Oncosil Medical iş modeli ve hisse analizi
Oncosil Medical hakkında sık sorulan sorular
The business model of Oncosil Medical Ltd focuses on developing and commercializing innovative medical devices for the treatment of various cancers. The company's flagship product, Oncosil™, is a minimally invasive implantable device that delivers a targeted dose of radiation directly to tumor sites. This unique approach aims to improve cancer treatment outcomes by enhancing the efficacy of radiation therapy while minimizing side effects. Oncosil Medical Ltd also collaborates with leading research institutions and medical centers to further advance the understanding and applications of its technology. By providing a targeted and precise treatment option, Oncosil Medical Ltd aims to improve the lives of cancer patients worldwide.
Oncosil Medical Ltd is primarily active in the healthcare industry.
The main competitors of Oncosil Medical Ltd in the market include medical companies such as Varian Medical Systems, Isoray Inc., and Monarch Medical Technologies.
Oncosil Medical Ltd is an Australian-based medical technology company specializing in the development and commercialization of innovative products for the treatment of cancer. Established in 1995, Oncosil Medical Ltd has since focused on enhancing radiotherapy treatments through its unique targeted radiation therapy approach. The company's flagship product, the OncoSil™ device, is designed to deliver localized radiation directly to tumors, providing a more effective and targeted treatment option for patients. With a strong commitment to improving patient outcomes, Oncosil Medical Ltd continues to innovate and expand its product pipeline, aiming to revolutionize cancer treatment worldwide.
Oncosil Medical Ltd has achieved several significant milestones. Firstly, the company successfully completed its pivotal global clinical trial for the use of OncoSil™ as a treatment for pancreatic cancer. This trial demonstrated positive results and paved the way for regulatory approvals. Secondly, Oncosil Medical Ltd received CE Mark approval in Europe, allowing for the commercialization of OncoSil™ in the European Union. Furthermore, the company secured regulatory approval from the Australian Therapeutic Goods Administration. These achievements mark Oncosil Medical Ltd's progress in developing innovative solutions for cancer treatment, positioning the company as a leader in the field.
Oncosil Medical Ltd is primarily present in Australia.
Oncosil Medical Ltd is a leading medical technology company dedicated to revolutionizing cancer treatment. The company's core values include innovation, excellence, and patient-centricity. Oncosil Medical is driven by a corporate philosophy that emphasizes cutting-edge research, strategic partnerships, and delivering effective and safe medical solutions to patients worldwide. By leveraging its expertise in radiotherapy and brachytherapy, Oncosil Medical aims to improve the quality of life for cancer patients and provide them with new hope. With a commitment to advancing cancer therapies, Oncosil Medical Ltd stands as a reliable and compassionate ally in the fight against cancer.
7 analist şu anda Oncosil Medical hissesini değerlendiriyor: 0 al, 3 tut, 4 sat öneriyor.
Güncel döviz kuruyla Oncosil Medical hissesi 0,40 EUR (0,65 AUD) seviyesindedir.
Oncosil Medical hissesi (OSL.AX) 1 borsada işlem görür, bunlar arasında: ASX (OSL.AX).
Oncosil Medical Ltd is an Australian-based medical company specializing in the development and marketing of innovative medical devices for tumor radiation therapy. The company aims to help cancer patients worldwide achieve a better quality of life.
'nin Oncosil Medical hasılatı 1,68 M AUD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
'nin Oncosil Medical karı -10,86 M AUD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Oncosil Medical'nin Fiyat/Kazanç (F/K) oranı şu anda -1,61'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Oncosil Medical hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Oncosil Medical'nin Fiyat/Satış (F/S) oranı şu anda 10,36'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Oncosil Medical hisse senedinin değerleme metriği olarak hizmet eder.
Oncosil Medical'nin Eulerpool Kalite Puanı 4/10'dur.
Oncosil Medical'nin ISIN'i AU000000OSL3'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Oncosil Medical'nin WKN'i A1WZU4'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Oncosil Medical'nin ticker'ı OSL.AX'dir. Ticker sembolü, Oncosil Medical hisseleri borsada işlem görmek için kullanılır.
Oncosil Medical Hissesi
Oncosil Medical Emsaller Grubu
Oncosil Medical Ticker
Oncosil Medical FIGI
Oncosil Medical'nin tüm temel göstergeleri ve derinlemesine analizi
Oncosil Medical hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Oncosil Medical şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: